-+ 0.00%
-+ 0.00%
-+ 0.00%

Truist Securities Maintains Buy on Beta Bionics, Raises Price Target to $22

Benzinga·07/13/2026 16:09:32
语音播报
Truist Securities analyst Richard Newitter maintains Beta Bionics (NASDAQ:BBNX) with a Buy and raises the price target from $18 to $22.